Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Study of the Biology and Natural History of Disease Outcomes in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
Background:
Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem
cells) have been used with varying degrees of success as an immune therapy for blood-system
cancers (leukemias, myelodysplastic syndrome, lymphomas, multiple myeloma, etc.). Some people
s cancer remains active (comes back or continues to spread) after an allotransplant, while
other peoples cancer disappears and they are hopefully cured. National Institutes of Health
(NIH) researchers are studying the reasons for these different treatment outcomes, and trying
to develop better cancer treatments for people with active cancer after allotransplant.
Researchers are collecting data from people who have had allotransplants for a cancer of the
blood, whether or not the cancer is in remission, and from their donors. Those with active
cancers may be eligible to participate in one of several NIH studies testing treatments for
active cancer after allotransplant.
Objectives:
- To develop a systematic, comprehensive evaluation of individuals with relapsed malignant
blood cancers after allotransplant (and, if available, their donors) to identify
potential treatment study options
- To compare the immune system after allotransplant between people whose cancers are
growing with people whose cancers remain in remission.
- To compare the immune system after cancer relapse/progression treatment between people
whose cancer responds to treatment with those whose cancers continue to grow.
Eligibility:
- Individuals whose blood system cancer grows or comes back after receiving allotransplant
treatment.
- Individuals whose blood system cancer is responding or in remission 100 days or more
after receiving allotransplant treatment.
- Related stem-cell donors of eligible allotransplant recipients.
Design:
- Participants will be evaluated with a full physical examination, detailed medical
history (for recipients, including a history of allotransplant treatment process,
side-effects, etc.), and blood tests. Recipients will also have imaging studies,
possible tissue biopsies, quality of life questionnaires/assessments, and other tests to
evaluate the current state of their cancer, whether active or in remission. In some
cases, it may be possible to substitute results from recent tests and/or biopsies.
- Healthy related donors will have apheresis to provide white blood cells for study and/or
for use in potential treatment options. If stem cells would be medically helpful to a
recipient, their donors might be asked to take injections of filgrastim before the
apheresis procedure to stimulate the production of stem cells for collection.
- As feasible, all recipients will be asked to return to the NIH for detailed follow-up
visits in conjunction with 6, 12, and 24 months post-allotransplant evaluations, and may
be monitored between visits.
- Recipients whose cancers are active and who are found to be eligible for treatment
protocols at the NIH will continue to be monitored on this study while participating on
treatment protocols. Return visits and follow-up tests for this study will be
coordinated with those required by the treatment protocol.
- Participants may return in the future to be evaluated for new treatment study options
(recipients) or additional cell donations for therapy (donors).
Background:
- Cancer relapse is a significant clinical problem following allogeneic hematopoietic stem
cell transplantation (allotransplant), affecting up to half of all patients. Effective
treatment options are extremely limited and, for most cancers, rarely curative.
- Several Clinical Center (CC) protocols are evaluating treatment for post-allotransplant
relapse. Relapse often progresses quickly; patients require rapid assessment of protocol
options in order to expedite initiation of treatment.
- Basic information is needed to improve management of relapse after allotransplant
clinical information regarding risk of relapse and cancer behavior after allotransplant,
and information on the biology of relapse after allotransplant in order to identify risk
factors, target prevention strategies, detect early relapse and develop effective
treatments.
Objectives:
Primary Objective:
To provide a mechanism for systematic, comprehensive evaluation of individuals with relapsed
hematologic malignancy after allotransplant and, if available, their donors, to streamline
identification of protocol options, enrollment and initiation of therapy.
Eligibility:
1. Individuals who have received allotransplant treatment for hematologic malignancy
("Recipient-Subjects"). Analyses (secondary aims) will consider two comparison cohorts:
1. Relapse Cohort: Cancer progression, relapse or persistently stable (unremitting)
disease
2. Remission (Control) Cohort: Cancer response or remission at/after Day 100
2. Individuals who are being enrolled on Clinical Center protocols to undergo
allotransplant therapy for hematologic malignancies and are being evaluated at the
Clinical Center for planned allotransplantation. (Recipient-Subjects)
3. Related donors of eligible allotransplant recipients ("Donor-Subjects")
Design:
1. Recipient-Subjects will have clinical and research evaluations at baseline and three and
six months post-allotransplant, at six-month intervals through three years
post-allotransplant, then yearly. Evaluation after relapse treatment response and for
new protocol options is permitted.
2. Donor-Subjects will be enrolled at the time of their clinical evaluation and cell
collection for Recipient-Subject therapy. Return evaluation for additional clinical
product collection is permitted.
3. Accrual Ceiling: 500 consented subjects (350 Recipient-Subjects and 150 Donor-Subjects)
over 5 years, averaging 70 Recipient-Subjects and 30 Donor-Subjects enrolled per year.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |